ArticleMedicine2026
Blood urea nitrogen as a predictor of 28-day mortality in ICU patients with multiple myeloma: A retrospective cohort study (MIMIC-IV, 2008-2019).
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma patients frequently develop acute kidney injury; yet, the prognostic value of early blood urea nitrogen (BUN) in the critical care setting remains unclear. This retrospective cohort study included 304 critically ill adults with multiple myeloma to evaluate BUN as a readily available biomarker for early risk stratification. Using the Medical Information Mart for Intensive Care-IV 3.1 database (2008-2019), we analyzed first-time intensive care unit admissions. BUN and all covariates were obtained within 24 hours of admission. Cox regression, restricted cubic splines, and Kaplan-Meier analyses estimated the association between BUN and 28-day all-cause mortality. Mean age was 72.6 ± 10.8 years; 61.5% were male. BUN tertiles were T1 <23 mg/dL, T2 23-44 mg/dL, and T3 >44 mg/dL. After multivariable adjustment, each 1 mg/dL rise in BUN increased mortality risk by 1% (hazard ratio [HR] 1.01, 95% confidence interval [CI] 1.01, 1.02). Compared with T1, 28-day mortality risk was higher in T2 (HR 3.47, 95% CI 1.45, 8.30) and T3 (HR 6.96, 95% CI 2.61, 18.61). A threshold effect was observed at 52.57 mg/dL, above which risk plateaued. Survival curves diverged early and remained separated across tertiles (log-rank P < .001); findings were consistent across predefined subgroups. These findings suggest that early BUN measurement can identify high-risk patients who may benefit from intensified monitoring and timely intervention. BUN levels measured within the first 24 hours of intensive care unit admission are independent, dose-dependent predictors of 28-day mortality in critically ill patients with multiple myeloma, supporting the use of BUN for early risk stratification. As an inexpensive and universally available biomarker, BUN holds promise for guiding clinical decision-making and resource allocation in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.